One of 47 tertiary general hospitals in 2024, Gangneung A Hospital of U University in Gangwon Province had initially decided to adopt the Anyfusion cylinder pump earlier this year based on favorable demo results before the healthcare crisis began. However, its purchase was immediately put on hold due to the crisis. We have now received notification of A Hospital's purchase decision and its first order.

This marks the third tertiary general hospital to list the Anyfusion cylinder pump. U University's A Hospital network includes Seoul A Hospital, Korea's premier tertiary general hospital, and Ulsan A Hospital, Ulsan's sole tertiary hospital, along with two additional general hospitals in Gangwon Province. With Gangneung A Hospital now listing the Anyfusion cylinder pump and cartridge set, momentum is building for launching at the remaining two U University-affiliated tertiary hospitals and the two general hospitals.

The shutdown issue, which was a concern during the program upgrade, has not occurred to date. While the air alarm frequency has been reduced to 2-3 times per day, matching the level of conventional drug infusion pumps, each patient typically requires 5-6 pumps as a baseline, with many using over 10. Consequently, the air alarm remains the greatest stressor for drug infusion pumps in critical care settings. No major global company has solved the core issue of pump air alarm stress in drug infusion pumps.

Through continuous R&D, we have developed technology that minimizes the air alarm frequency from 2-3 times per day to just 1-2 times over 4-7 days. We plan to launch the patented Anyfusion cylinder pump, which resolves the core global issue of air alarm stress in drug infusion pumps, next month in September.

By minimizing air alarms and completely overcoming the internal leakage issues of existing pumps, its groundbreaking clinical utility is expanding usage at existing user hospitals through recommendations from other departments and word of mouth. With confidence and conviction, demonstrations are also planned at S University Hospital, Korea's top university hospital, and Y University Hospital, the second-ranked university hospital. Gyeonggi Province's A University Hospital has registered its code to conduct demonstrations and use the Anyfusion cylinder pump for SCI paper publications, domestic and international conference presentations, and exhibition promotions. This is part of a real-world evidence support project addressing not only the FDA's STeP-identified issues of fluid retention within existing pumps but also various core user concerns resolved by the Anyfusion cylinder pump.

Contracts have been secured to expand booths at UAE Arab Healthcare and Germany's MEDICA for the Anyfusion cylinder pump and new product ACPi Pro. The successful clinical results from domestic hospitals will provide a groundbreaking competitive edge to replace global imported pumps, shifting the paradigm of global drug infusion pumps to the Anyfusion style. In other words, it will be a game changer.

Amidst the healthcare crisis, with severe financial deficits at tertiary hospitals and the inability to register or purchase new medical devices or drugs, the Anyfusion demo and purchase hold significant meaning. More critical than severe financial hardship are the serious safety and reliability issues with existing infusion pumps. Coupled with the government's policy to prioritize critical care in tertiary hospitals, demand for pumps supplying drugs and fluids to critical patients is rising. This, combined with the need to replace aging pumps, creates perfect clinical safety and reliability. Overcoming practitioner concerns, the innovative Anyfusion cylinder pump demo results led to its selection, though the initial order is small. 

To increase purchase volume, become a world-leading product (premium brand), achieve a paradigm shift in the global market (monopoly product), and establish ourselves as the world's top company, the following processes and steps seem necessary based on past experience and the current situation:

1. Innovative product development (world-class innovation does not automatically guarantee rapid marketization) 2. Publishing evidence from research processes, pre/post-approval clinical trials, and real-world references 3. Enhancing product completeness based on real-world usage references 4. Ensuring reliability for mass and long-term use 5. Real-time A/S and C/S 6. Next-generation innovation items (ACPi Pro) and products (HIS-linked cylinder pump development) 7. Will and funding.

Steps 4 and 5, validated domestically and internationally, are expected to drive a sharp increase in sales volume, positioning us as a global product and company. Step 6 is considered essential for advancing to higher levels, while Step 7 is deemed a perpetually necessary stage.

To date, we have steadily completed each stage thanks to our shareholders' support.

We will now do our utmost to deliver promising results to our shareholders in the shortest possible time.

Thank you.